Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GOCO
4326
DELISTED
GoHealth
GOCO
| $175K | ﹤0.01% |
81,181
+7,430
| +10% | +$25.4K |
|
4327
Sagimet Biosciences
SGMT
$599M
| $174K | ﹤0.01% |
29,338
+22,929
| +358% | +$165K |
|
4328
Journey Medical
DERM
$176M
| $174K | ﹤0.01% |
22,521
+4,955
| +28% | +$38.9K |
|
4329
Transcontinental Realty Investors
TCI
$324M
| $174K | ﹤0.01% |
2,960
+282
| +11% | +$13.4K |
|
4330
FT Vest US Equity Deep Buffer ETF July
DJUL
$458M
| $173K | ﹤0.01% |
3,644
-505
| -12% | -$23.8K |
|
4331
LENSAR
LNSR
$74.4M
| $173K | ﹤0.01% |
14,857
+1,389
| +10% | +$15.9K |
|
4332
TTEC Holdings
TTEC
$80.8M
| $170K | ﹤0.01% |
47,274
+389
| +0.8% | +$1.32K |
|
4333
GSI Technology
GSIT
$253M
| $170K | ﹤0.01% |
+27,367
| New | +$195K |
|
|
SII
4334
Sprott
SII
$3.08B
| $170K | ﹤0.01% |
1,734
+1,320
| +319% | +$117K |
|
|
ARX
4335
Accelerant Holdings
ARX
$2.81B
| $170K | ﹤0.01% |
+10,375
| New | +$146K |
|
4336
NI Holdings
NODK
$313M
| $170K | ﹤0.01% |
12,749
+1,359
| +12% | +$18.3K |
|
|
AUGM
4337
FT Vest U.S. Equity Max Buffer ETF - August
AUGM
$31.8M
| $169K | ﹤0.01% |
+4,977
| New | +$168K |
|
4338
Global X MLP & Energy Infrastructure ETF
MLPX
$3.56B
| $169K | ﹤0.01% |
+2,788
| New | +$167K |
|
4339
PLAYSTUDIOS Inc
MYPS
$77.1M
| $168K | ﹤0.01% |
258,456
+13,346
| +5% | +$10.4K |
|
|
ISBA
4340
Isabella Bank
ISBA
$308M
| $168K | ﹤0.01% |
+3,361
| New | +$142K |
|
4341
FT Vest US Equity Max Buffer ETF March
MARM
$108M
| $168K | ﹤0.01% |
5,079
-723
| -12% | -$23.7K |
|
|
DGOC
4342
FT Vest U.S. Equity Buffer & Digital Return ETF - October
DGOC
$4.91M
| $168K | ﹤0.01% |
+5,380
| New | +$166K |
|
4343
CALL
Corcept Therapeutics
CORT
$12.2B
| $167K | ﹤0.01% |
4,800
-120,800
| -96% | -$9.49M |
|
4344
Methanex
MEOH
$4.17B
| $167K | ﹤0.01% |
4,199
+2,249
| +115% | +$83.7K |
|
4345
PUT
ChargePoint
CHPT
$159M
| $166K | ﹤0.01% |
25,000
| – | – |
|
4346
One Stop Systems
OSS
$332M
| $166K | ﹤0.01% |
23,094
+19,588
| +559% | +$116K |
|
|
KZIA
4347
Kazia Therapeutics
KZIA
$160M
| $165K | ﹤0.01% |
23,999
-1
| -0% | -$9 |
|
4348
Barings BDC
BBDC
$970M
| $165K | ﹤0.01% |
+18,000
| New | +$159K |
|
4349
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$12B
| $164K | ﹤0.01% |
1,145
| – | – |
|
4350
InnovAge Holding
INNV
$1.41B
| $164K | ﹤0.01% |
31,591
+3,040
| +11% | +$16K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.